CDMO SERVICES

A dedicated solution provider of cellular therapy products

CAR-T
CDMO Services for CAR-T Cells - Clinical grade

CAR-T cells, i.e. the Chimeric Antigen Receptor T Cell, work in the principle of utilizing the patient’s own T lymphocytes, which are re-engineered in the lab, loaded with receptors recognizing the tumor-antigen, proliferated ex vivo, and subsequently re-infused to the patient, to recognize and attack the tumor cells. Hillgene is specialized in provision of integrated CDMO solutions for cellular therapy products, has established a completely closed process development platform for cellular therapy products, and therefore, can provide high-quality CDMO services for cells to clients with various demands.

Services 

CDMO Services for CAR-T Cells (HiCellx® Platform)
TypesServices
Clinical grade1GMP Manufacturing of CAR-T Cells

● Production scale: 200 mL~20 L (subject to customized changes)

● Process route: flexible process design and subject to customized changes

● Full-GMP compliant Workshop of B+A grade with unidirectional air flow

● GMP quality management system

● Involving in ongoing clinical studies

2Technology Transfer

● Technology transfer

● Receiving technology transfer

● Well-established plan for technology transfer

● Well-established plan for receiving technology transfer

● Plan for transferring different technologies across different phases

*Note: We offer relatively flexible and customized changes to above services, including but not limited to above services. 



Advantages

Advantages of using our HiCellx® technology platform:

• Using independently developed cryopreserved cell preparation 

• Using closed and automated cell culturing equipment, the same as the global mainstream companies

• Cell workshop compliant with clinical and commercial requirements: grades B+A, unidirectional air flow, Full-GMP

• Cell proliferation with higher rate, solved the issues of low positive rate and proliferation rate

• Flexibly suitable for manufacturing and testing of various cellular therapy products 

• Extensive experience in using the closed and automated cell culturing equipment 

• Experience in manufacturing of 200+ IIT clinical samples 

• Experience in IND submission of a CAR-T cell product, which was successfully approved by NMPA

• Experience in supporting the technology transfer of clinical batch of CAR-T cell products and in manufacturing of cell samples for clinical use



Manufacturing process

627cd51c36dc1.jpg


Quality control

TypesTest ItemTest Method
Routine testsAppearanceVisual inspection
pHMethod 0631 of ChP 2020
OsmolalityMethod 0632 of ChP 2020
Cellular characteristics/functionsCell countsFluorescence staining
Cell viabilityFluorescence staining
CAR positive rateFlow cytometry
Immune cell compositionFlow cytometry
Cytokine secretionELISA
CytotoxicityAs per Protocol
ImpurityResidual culture supplementDepending on supplement type
Residual magnetic bead countMicroscopy
SafetyNumber of CAR gene copiesq-PCR
Endotoxin testingMethod 1143 of ChP 2020
Sterility testing

Rapid testing

Method 1101 of ChP 2020
Mycoplasma testingq-PCR
Method 3301 of ChP 2020
RCLq-PCR 

*Note: Hillgene established QC methods corresponding to different technology platforms, with QC methods including but not limited to above items. 



Project Timeline

628218d3b06d1.jpg



Project Management Plan

Hillgene Project Management Team, consisting of chief scientists, project managers, Project QA and GMP experts, will make efforts to ensure the smooth and sound operation of each and every GMP project.

周会.png